EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

A new technology: renal nerve mapping+selective denervation A new technology: renal nerve mapping+selective denervation In the SMART study, patients in the msRDN arm have eight mapped sites on unilateral renal artery on average, nearly 50% of which are "hot spots" requiring ablation (4 sites on each artery) and 39.4% of the hot spots require a second ablation (1.5 sites on each artery). Post-ablation feedback mapping ensures effective renal sympathetic denervation by indicating the...

A new technology: renal nerve mapping+selective denervation

In the SMART study, patients in the msRDN arm have eight mapped sites on unilateral renal artery on average, nearly 50% of which are "hot spots" requiring ablation (4 sites on each artery) and 39.4% of the hot spots require a second ablation (1.5 sites on each artery). Post-ablation feedback mapping ensures effective renal sympathetic denervation by indicating the necessity of a second ablation of each site. Compared to RDN systems without mapping and feedback , the innovative approach of 'renal nerve mapping+selective denervation' greatly enhances intraoperative feedback, thus avoiding complications caused by blind ablations and eliminating uncertainty of operation outcome.

A new endpoint: effective BP control and significant change in the composite drug index proves major benefit of msRDN

In the 6 months follow-up with a strict drug regimen, the msRDN group demonstrated effective blood pressure control. The 6-month office BP and 24h ambulatory BP lowered significantly compared to baseline, reducing ODBP by 25mmHg, ambulatory DBP by 12mmHg, 24h dynamic SBP by 10.8mmHg, and 24h dynamic DBP by 6.3mmHg. OSBP control rate of the msRDN group was 95% with significantly reduced drug burden compared to the sham group.

The result is a resounding prove that patients in the msRDN group can achieve satisfactory BP control with markedly lower anti-hypertensive drug dosage.

Photo - https://mma.prnewswire.com/media/2080970/SyMap_Medical.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/europcr-2023--6-month-outcome-of-the-smart-study-satisfactory-bp-control-achieved-with-reduced-medication-burden-301829331.html